N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 3 ClinicalTrials.gov

Benefits of ADHD Treatment in Detained People

Sponsor: Stéphanie Baggio • ClinicalTrials.gov ID: NCT05842330

Registry updated: 2026-09-21
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Attention deficit hyperactivity disorder (ADHD) is characterized by difficulties paying attention, poor impulse control, and hyperactive behaviors. It is associated with several health and social detrimental outcomes and leads to increased risks of criminality and recidivism. However, to date, ADHD treatment has been neglected in prison. This project will test the efficacy of ADHD treatment using a randomized controlled trial.

Interventions

  • Concerta (Drug)
    Dosages of Concerta® will be defined according to the Swiss Compendium (from 18 to 72 mg/d). The psychiatrist will start with the smallest dosage (18 mg) and will adapt it on a weekly basis or on need, depending on tolerance (side effects measured at each visit), clinical response (subjective improvement felt by the patient in terms of attention, impulsivity, and hyperactivity), and according to the observations made by the professionals or patient's entourage in term of attention, impulsivity, hyperactivity, and for this project, behavioral problems. In general, the dose can be increased in 18 mg at weekly intervals. The treatment will be monitored weekly the first month, and then monthly, except for side effects which will be monitored daily in prison and every two weeks after release.
  • Placebo (Drug)
    The placebo will be strictly identical (same packaging, size no. 2 and color according to dosage, with no label). Procedure for adjustment of dosage will be the same as in the Concerta arm.

Eligibility criteria

Inclusion Criteria: * age between 18 and 65 * good command of French * stay in prison approx. 4 months at eligibility visit * endorsing clinical diagnostic criteria for DSM-5 ADHD * providing written informed consent Exclusion Criteria: * presence of an acute uncontrolled comorbid psychiatric disorder * medical contraindication to stimulant prescription * potential adverse interaction with another medication * already receive ADHD treatment

Conditions

ADHD

Locations

  • Geneva University Hospitals — Geneva, Canton of Geneva, Switzerland
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record